Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | HPN | P05981 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.48 |
| ▸ | GLRB | P48167 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.44 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20657093 | 0.82 | CA2 (0.65) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL16512751 | 0.77 | CA2 (0.43) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL2320419 | 0.75 | CA2 (0.64) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL29462687 | 0.74 | CA2 (0.62) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL16383545 | 0.73 | SMN1; SMN2 (0.58) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL5589360 | 0.73 | GLRA3 (0.50) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL18272165 | 0.73 | GABRA1 (0.46) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL5588373 | 0.73 | CA2 (0.48) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL15173818 | 0.72 | CA2 (0.59) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL9244593 | 0.72 | SMN1; SMN2 (0.64) | CA2CA1SMN1; SMN2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | CA2 2455/4885CA1 3572/4885SMN1; SMN2 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.